New cancer drug tested for Tough-to-Treat tumors
NCT ID NCT04175847
Summary
This early-stage study tested a new drug called RC88 in 198 patients with advanced solid tumors that had stopped responding to standard treatments. The main goals were to find a safe dose and see if the drug showed any early signs of slowing cancer growth. The study focused on cancers like mesothelioma and ovarian cancer that produce a specific protein called MSLN.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMOR are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Drum Tower Hospital
Nanjing, Jiangsu, China
-
Henan Cancer Hospital
Zhengzhou, Henan, 450008, China
-
National Cancer Center/Cancer Hospital, Chinese Academy of Medical Science and Peking Union Medical College
Beijing, Beijing Municipality, 100021, China
-
The First Hospital of Jilin University
Changchun, Jilin, 130021, China
Conditions
Explore the condition pages connected to this study.